Ontology highlight
ABSTRACT:
SUBMITTER: Maselli DJ
PROVIDER: S-EPMC6205543 | biostudies-literature | 2018
REPOSITORIES: biostudies-literature
Therapeutics and clinical risk management 20181023
There are now multiple monoclonal antibodies targeting different inflammatory pathways of severe asthma. Benralizumab is a recently approved monoclonal antibody indicated for the treatment of severe eosinophilic asthma by targeting a subunit of the IL-5 receptor. Treatment with benralizumab results in significant reductions of blood and tissue eosinophils. Early studies report that this therapy has an adequate safety profile, and this was confirmed in later trials. Phase III studies have shown t ...[more]